An interventional study of AirSeal System and Standard Endopath in Prostate Cancer and Pneumoperitoneum, sponsored by OhioHealth. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-26.
Sponsored by OhioHealth · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.
Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 867th largest by enrollment of the 3,024 interventional ones that give a count, is one of 137 that started in 2016, is one of 764 with no phase, and was the 1,560th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–80 · Men only
City of Hope Medical Center · Sites in United States
Ages 40–80 · Men only
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Men only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 50–75 · Men only · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,597 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 899 · Phase 2 1,384 · Phase 3 321 · Phase 4 50
First in 1988; this study’s year is marked. 137 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 48 across the 3,024 interventional studies, 158 across the 478 observational. Of the 2,360 that completed or were terminated, 997 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
922 of 3,597 have an industry lead sponsor. The 10 most frequent:
OhioHealth is the lead sponsor of 25 studies on the registry; none are open to participants now.
OhioHealth has 3 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
334 of the studies in Prostatic Neoplasms with a site in United States that are under way reach primary completion within a year, 24 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT06970847Phase 3Clarity Pharmaceuticals Ltd64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | 2026-12-31 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT07427043Phase 3Brigham and Women's HospitalRobotic Opioid-free Prostatectomy Enhanced Strategy (ROPES) | 2026-12-31 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
Add all 334 to your calendar (.ics) → With an account.
Among the 3,597 studies in Prostatic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The AirSeal® System will allow for lower carbon dioxide (CO2) absorption rates than the standard Endopath System.
The primary observation to be made is the level of carbon dioxide in the arterial blood, specifically when the patient is insufflated and deflated during the surgery. As a result of the consistent pressure that the AirSeal® system maintains, carbon dioxide will be absorbed in lower levels when compared to the standard of care systems in which fluctuations in intra-peritoneum pressure are seen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group receives the AirSeal System for intraoperative insufflation.
Device: AirSeal System
This group receives the Standard Endopath Trocar for intraoperative insufflation.
Device: Standard Endopath
To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.
Also known as: Valve-free Trocar
This group receives the Standard Endopath Trocar for intraoperative insufflation.
Also known as: Endopath Trocar
Intraoperative Pneumoperitoneal Pressure (mmHg)
Pneumoperitoneal pressure is the pressure exerted by air or gas in the abdominal (peritoneal) cavity. As the amount of air/gas increases, the pressure (mmHg) increases. The highest pressure that occurred during the procedure was compared between groups.
Time frame: Through end of procedure, an average of 156 minutes
Intraoperative Arterial Blood Gas Carbon Dioxide (mmHg).
The amount of dissolved carbon dioxide (PaCO2) in arterial blood (mmHg) during the operative procedure
Time frame: Baseline, 60 minutes, and at end of procedure, an average of 156 minutes
End-tidal Carbon Dioxide Pressure (mmHg)
End-tidal carbon dioxide pressure is the partial pressure of carbon dioxide at the end of exhalation. Normal value is 35-45 mmHg.
Time frame: Baseline, 60 minutes, and at end of procedure, an average of 156 minutes
Carbon Dioxide Elimination (mmHg)
Carbon dioxide elimination was calculated using end-tidal carbon dioxide pressure (EtCO2), tidal volume, respiratory rate, barometric pressure (pB = 760mm Hg), partial pressure of water vapor (PH2O = 13 mm Hg), and patient weight (kg)
Time frame: Baseline, 60 minutes, and at end of procedure, an average of 156 minutes
Intraoperative Arterial Blood Gas Oxygen (mmHg).
The amount of dissolved oxygen (PaO2) in arterial blood (mmHg).
Time frame: Baseline, 60 minutes, and end of procedure, an average of 156 minutes
Number of Ventilator Interventions
The number of times the anesthesiologist had to adjust ventilator settings
Time frame: Through end of procedure, an average of 156 minutes
Procedure Time (Minutes)
The duration of the procedure
Time frame: Through end of procedure, an average of 156 minutes
Smoke Evacuation Quality
Smoke evacuation quality throughout the procedure was assessed by the surgeon as below average, average, or above average
Time frame: Through end of procedure, an average of 156 minutes
| Milestone | AirSeal System | Standard Endopath |
|---|---|---|
| Started | 50 | 50 |
| Completed | 50 | 50 |
| Not completed | 0 | 0 |
Pneumoperitoneal pressure is the pressure exerted by air or gas in the abdominal (peritoneal) cavity. As the amount of air/gas increases, the pressure (mmHg) increases. The highest pressure that occurred during the procedure was compared between groups.
| mmHg | AirSeal System | Standard Endopath |
|---|---|---|
| Intraoperative Pneumoperitoneal Pressure (mmHg) | 7.9 ± 2.5 | 9.9 ± 2.9 |
The amount of dissolved carbon dioxide (PaCO2) in arterial blood (mmHg) during the operative procedure
| mmHg | AirSeal System | Standard Endopath |
|---|---|---|
| Baseline | 39.5 ± 4.9 | 39.2 ± 5.3 |
| 60 minutes | 41.5 ± 7.7 | 41.2 ± 5.2 |
| End of procedure | 45.1 ± 6.1 | 44.1 ± 5.5 |
End-tidal carbon dioxide pressure is the partial pressure of carbon dioxide at the end of exhalation. Normal value is 35-45 mmHg.
| mmHg | AirSeal System | Standard Endopath |
|---|---|---|
| Baseline | 31.47 ± 3.9 | 29.96 ± 3.1 |
| 60 Minutes | 32.80 ± 3.6 | 30.96 ± 3.2 |
| End of procedure | 34.77 ± 8.9 | 34.17 ± 7.2 |
Carbon dioxide elimination was calculated using end-tidal carbon dioxide pressure (EtCO2), tidal volume, respiratory rate, barometric pressure (pB = 760mm Hg), partial pressure of water vapor (PH2O = 13 mm Hg), and patient weight (kg)
| mmHg | AirSeal System | Standard Endopath |
|---|---|---|
| Baseline | 3.15 ± 0.67 | 3.28 ± 0.64 |
| 60 minutes | 3.24 ± 0.74 | 3.28 ± 0.6 |
| End of procedure | 3.04 ± 1.35 | 3.11 ± 0.65 |
The amount of dissolved oxygen (PaO2) in arterial blood (mmHg).
| mmHg | AirSeal System | Standard Endopath |
|---|---|---|
| Baseline | 361.9 ± 79.3 | 364.3 ± 81.9 |
| 60 minutes | 283.9 ± 115.4 | 294 ± 105.0 |
| End of procedure | 286.5 ± 99.1 | 290.2 ± 99.4 |
The number of times the anesthesiologist had to adjust ventilator settings
| Count of interventions | AirSeal System | Standard Endopath |
|---|---|---|
| Number of Ventilator Interventions | 0.69 ± 1.1 | 0.66 ± 0.9 |
The duration of the procedure
| Minutes | AirSeal System | Standard Endopath |
|---|---|---|
| Procedure Time (Minutes) | 158.6 ± 22.4 | 153.0 ± 19.9 |
Smoke evacuation quality throughout the procedure was assessed by the surgeon as below average, average, or above average
| Participants | AirSeal System | Standard Endopath |
|---|---|---|
| Below Average | 4 | 16 |
| Average | 25 | 18 |
| Above Average | 20 | 14 |
Collected over Through hospital discharge, an average of 8.4 hours. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AirSeal System | 0/50 (0%) | 0/50 (0%) | 1/50 (2%) |
| Standard Endopath | 0/50 (0%) | 0/50 (0%) | 3/50 (6%) |
| Event | AirSeal System | Standard Endopath |
|---|---|---|
| NauseaGastrointestinal disorders | 1/50 | 3/50 |
| Age, Continuous(years) | AirSeal System | Standard Endopath | Total |
|---|---|---|---|
| Mean | 61.0 ± 5.6 | 62.0 ± 6.7 | 61.5 ± 6.2 |
| Sex: Female, Male(Participants) | AirSeal System | Standard Endopath | Total |
|---|---|---|---|
| Female | NA | NA | NA |
| Male | 50 | 50 | 100 |
| Race/Ethnicity, Customized(Participants) | AirSeal System | Standard Endopath | Total |
|---|---|---|---|
| Race/Ethnicity — Caucasian | 50 | 42 | 92 |
| Race/Ethnicity — African American | 0 | 7 | 7 |
| Race/Ethnicity — Other | 0 | 1 | 1 |
| Region of Enrollment(participants) | AirSeal System | Standard Endopath | Total |
|---|---|---|---|
| United States | 50 | 50 | 100 |
| Body Mass Index (BMI)(kg/m^2) | AirSeal System | Standard Endopath | Total |
|---|---|---|---|
| Mean | 29.1 ± 4.3 | 28.3 ± 3.3 | 28.7 ± 3.8 |
| Preoperative hemoglobin(g/dL) | AirSeal System | Standard Endopath | Total |
|---|---|---|---|
| Mean | 15.1 ± 1.0 | 14.7 ± 1.0 | 14.8 ± 1.0 |
| Preoperative creatinine(mg/dL) | AirSeal System | Standard Endopath | Total |
|---|---|---|---|
| Mean | 0.89 ± 0.1 | 0.96 ± 0.2 | 0.92 ± 0.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Aug 2016, a primary completion of May 2018 and a completion of Jul 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2021, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
OhioHealth